Vasa Denticity Limited Q2 Revenue Rises 19.4% to Rs 87.1 Crore

Vasa Denticity Limited reported consolidated Q2 FY27 revenue of Rs 87.10 crore, up 19.4% year-on-year, while operating profit increased 24.0% to Rs 7.24 crore. The result reflected improved own-brand product availability, a recovery in gross margin and lower operating costs, with the share price up 3.1% so far on November 10, 2026.

What did Vasa Denticity report for Q2 FY27?

Vasa Denticity reported revenue from operations of Rs 87.10 crore for the quarter ended September 30, 2026, compared with Rs 83.14 crore in the preceding quarter and a 19.4% increase from a year earlier. Revenue grew 4.8% sequentially, taking first-half FY27 revenue to Rs 170.24 crore, a 27.6% year-on-year increase.

Operating profit, reported as operating EBITDA, was Rs 7.24 crore. This was 42.8% higher than Rs 5.07 crore in Q1 FY27 and 24.0% higher year-on-year. Profit before depreciation and tax was Rs 7.78 crore, while profit before tax stood at Rs 6.96 crore.

Profit after tax was Rs 5.20 crore, up 28.4% sequentially from Rs 4.05 crore and 12.1% year-on-year, according to the quarterly results summary. The company filed its investor presentation with the National Stock Exchange of India on November 10, after the board approved the unaudited results on November 6 following an audit committee review.

Why did Vasa Denticity's margins improve sequentially?

Vasa's gross margin improved to 27.2% in Q2 FY27 from 23.7% in Q1 FY27, a sequential expansion of 239 basis points. The company attributed the improvement to better availability of its own-brand products, which had faced availability constraints in the earlier quarter.

The company also reported a 10.5% reduction in operating costs as automation lowered the cost per order. These two developments supported the faster sequential increase in operating profit relative to revenue. Operating EBITDA margin was reported at 8.3%, up 222 basis points from the preceding quarter.

The gross margin remained 599 basis points lower than the year-earlier quarter, according to the presentation. This distinction is relevant because the quarter showed a clear recovery from Q1 FY27, but it did not fully reverse the year-on-year gross-margin movement.

How is Vasa Denticity managing product availability and inventory?

Vasa held inventory of Rs 104 crore to reduce stock-outs, which were reported at 8.8%. The inventory position is central to the company's stated effort to improve the availability of products, particularly its own brands, and thereby support sales conversion and gross margin.

The company said it expects a higher sales scale to bring down inventory days. It did not provide a specific inventory-days target or a timeframe in the disclosed presentation. Therefore, the reported inventory level should be viewed alongside the stated operational objective of reducing stock-outs rather than as a stand-alone financial metric.

Vasa also reported cash of Rs 39 crore and almost no debt. This balance-sheet position gives context to the inventory investment, although the presentation does not state a separate funding plan or capital-expenditure programme for the quarter.

What does the Q2 result mean for Vasa Denticity investors?

For investors, the Q2 FY27 update showed revenue growth of 19.4% and operating-profit growth of 24.0%, with the latter aided by a sequential margin recovery and lower operating costs. The difference between operating-profit growth and profit-after-tax growth also indicates that the improvement was more pronounced at the operating level.

Vasa's share price was up 3.1% so far on November 10, 2026, based on the provided market update. The movement followed the investor presentation and reflects the market's response during the day, not a measure of longer-term performance. The cited NSE price was Rs 462.00 on November 9, 2026.

The results are consolidated and include Vasa Denticity Limited with Waldent Innovations Private Limited, Smileworks Private Limited and Dentalkart Distribution UK Limited. Investors comparing periods should also note that the financial statements were unaudited and subject to limited review by KRA & Co., Chartered Accountants.

What are the important dates and figures from the update?

The key disclosed dates are the September 30, 2026 quarter-end, the November 6 board approval and the November 10 exchange intimation of the investor presentation. The presentation covers the quarter and half year ended September 30, 2026.

The first half figures show that Q2 added Rs 87.10 crore to H1 revenue of Rs 170.24 crore. The June quarter had reported revenue of Rs 83.14 crore, operating EBITDA of Rs 5.06 crore and profit after tax of Rs 4.12 crore in the company's earlier presentation.

Conclusion

Vasa Denticity's Q2 FY27 performance was marked by 19.4% revenue growth, a 24.0% rise in operating profit and a sequential recovery in gross margin to 27.2%. Improved own-brand availability and automation-led cost reduction were the stated drivers, while the Rs 104 crore inventory balance was positioned as a measure to curb stock-outs.

The next factors to watch are whether sales growth lowers inventory days as the company expects, whether stock-outs improve from 8.8%, and whether the sequential gross-margin recovery can be sustained. The company has not disclosed an earnings-call transcript for the quarter, so the available information is based on its investor presentation and results filing.